StockGuru News: Response Biomedical and EntreMetrix
Response Biomedical Corp. (OTCBB: RPBIF) & (TSX.V: RBM) Response Biomedical Initiates US Clinical Trials of RAMP NT-proBNP Test for the Diagnosis of Congestive Heart Failure VANCOUVER, Aug. 3 /CNW/ - Response Biomedical Corporation (TSX-V: RBM, OTCBB: RPBIF) announced today it has begun patient enrollment at four leading sites in the United States for the purpose of demonstrating substantial equivalence of the RAMP NT-proBNP Test to a predicate device. The results of this multi-center clinical trial will form the basis for a US FDA 510(k) submission and European CE Certification. The four sites conducting the trials are the Mayo Clinic, Minneapolis…